Maryann Mugo, MD
Endocrinology, Diabetes & Metabolism · Taylorsville, GANPI 1235173485
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,966 of the $13,042 with a category attached, or 68.7%. Amgen accounts for 82.0% of it on its own, with 40 other manufacturers making up the rest. 2025 is the largest year on record at $6,325, 9.4 times the $676 reported in 2019.
Across 169 payments — averaging $77.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11K
- Insulet Corporation$255
- Dexcom, Inc.$226
- Valeritas, Inc.$187
- AstraZeneca$116
- Sanofi-aventis U.S. LLC$111
- plus $1K from 35 others
What the payments were for
- Speaking & faculty fees$8,96669%
- Travel & lodging$7486%
- Food & beverage$3,26925%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$3,741
- Omnipod$143
- DEXCOM G6 CGM SYSTEM$105
How this compares
$13,042 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $245,104 |
| MounjaroTirzepatide | 104 | $153,933 |
| TrulicityDulaglutide | 65 | $92,171 |
| JardianceEmpagliflozin | 64 | $78,415 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $51,503 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $49,278 |
| FarxigaDapagliflozin Propanediol | 44 | $48,274 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $45,023 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $21,782 |
| Humalog Kwikpen U-100Insulin Lispro | 62 | $20,504 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $19,839 |
| RybelsusSemaglutide | 19 | $19,095 |
| SynthroidLevothyroxine Sodium | 185 | $19,013 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $18,230 |
| Novolog FlexpenInsulin Aspart | 46 | $13,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $66 | $275,330191 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $88 | $251,864193 claims |
| Boehringer IngelheimJardiance | $86 | $78,41564 claims |
| AstraZenecaFarxiga | $116 | $48,27444 claims |
| AbbVieSynthroid | $36 | $19,013185 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,916241 claims |
| Sanofi-aventis U.S. LLCLantus | $111 | $2,61212 claims |
| IBSA Pharma Inc.Tirosint | $47 | $2,13913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Taylorsville
- Dawn Smiley-ByrdTaylorsville$385K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.